551st MEETING, ST. ANDREWS 1265 with a molecular weight of about 30000 and an isoelectric point of 4.5. This suggested that thyroid-stimulating hormone and thyroid-stimulating antibody molecules bound to the same receptor molecule. However, Scatchard analysis of the effects of thyroidstimulating immunoglobulins on the binding of thyroid-stimulating hormone to thyroid membranes gave linear plots (in direct contrast with the effects ot thyroid-stimulating hormone alone), which suggested that the immunoglobulins bound to a single population of membrane sites and were able to obscure the heterogeneous nature of the thyroidstimulating hormone receptor. This was probably due to the large immunoglobulin molecule completely blocking access of thyroid-stimulating hormone to the thyroid membrane, Prostaglandin El inhibits platelet aggregation induced by ADP, adrenaline, thrombin, collagen, antigen-antibody complexes and 5-hydroxytryptamine (for review see Bousser, 1973) . To our knowledge, the only agents capable of inducing platelet aggregation that is not inhibited by prostaglandin El are U.V. light (Dickson et al., 1971) and dithiothreitol (MacIntyre & Gordon, 1974) . Both these stimuli are known to cleave disulphide bonds (Jagger, 1967; Cleland, 1964) , and the aggregation reponses induced by these agents have many similarities. Dithiothreitol has a dual action on blood platelets; low concentrations inhibit ADP-or collagen-induced platelet aggregation, but higher concentrations directly induce aggregation. There are inter-species differences in the aggregation response to dithiothreitol; human platelets aggregate readily, but rat platelets respond poorly.
higher concentrations directly induce aggregation. There are inter-species differences in the aggregation response to dithiothreitol; human platelets aggregate readily, but rat platelets respond poorly.
Johnson et al. (1973) reported that the inhibitory action of prostaglandin El on ADP-induced platelet aggregation was decreased by dithiothreitol and increased by N-ethylmaleimide, a reagent which alkylates thiol groups. These authors concluded that the prostaglandin receptor on platelets contained functionally important thiol groups, but there was no report of the effects of dithiothreitol or N-ethylmaleimide alone on platelet aggregation. The present communication describes the effects of these thiol reagents and prostaglandin El, alone and in combination, on human and rat platelets, in an attempt to establish the possible importance of thiol groups in the prostaglandin receptor site on blood platelets.
Human blood was obtained by antecubital venepuncture from donors who had ingested no aspirin within the preceding 10 days. Rat blood was obtained from the inferior vena cava of animals under light ether anaesthesia. Blood samples were anticoagulated with trisodium citrate (final concentration 3.8mg/ml in human samples and 3.1 mg/ml in rat samples) and platelet-rich plasma was prepared by differential centrifugation. Platelet aggregation was recorded photometrically (Born, 1962) in 0.1 ml samples of platelet-rich plasma in a Bryston aggregometer with modified sample holder and lightpath. Aggregation responses were measured as the maximum increase in light transmission obtained after adding ADP. Prostaglandin El was dissolved in 95 % ethanol and subsequently converted into the sodium salt by addition of Na,C03. Portions (0.5rnl) of a 1 mg/ml solution were stored at -2O"C, and further dilutions made with iso-osmotic saline. ADP was dissolved in iso-osmotic saline, stored at -20°C and thawed just before use. Dithiothreitol and N-ethylmaleimide were dissolved in iso-osmotic saline and used within 4 h of preparation.
ADP, when added to human platelet-rich plasma, directly causes primary aggregation, and higherconcentrations causeasecondary aggregation due to therelease ofendogenous platelet constituents. The concentration of ADP added to human platelet-rich plasma was kept below the threshold for second-phase aggregation, and concentrations giving 50% of maximum primary aggregation were used. In rat platelet-rich plasma there is no secondary aggregation to ADP and again a concentration giving 50% of maximum response was used. Concentrations of ADP used were 1 -2 p~ in humans and 1.5-3p~ in rats. Platelet-rich plasma was preincubated at 37°C for 2min before the addition of ADP, and prostaglandin El was added to the platelet-rich plasma 30s before ADP. An equivalent volume of iso-osmotic saline was added to control samples in place of prostaglandin El. When the effects of dithiothreitol or N-ethylmaleimide were investigated, the thiol agent was added 90s before ADP. These experimental conditions are identical with those described by Johnson et al. (1973) . Prostaglandin El inhibited ADP-induced aggregation in both rat and human plateletrichplasma.Theconcentration of prostaglandin El that inhibited aggregatioiiby 53 % (thc I.C.50) was determined; I.C.50 values were 13 ng/ml in rat platelet-rich plasma and long/ ml in human platelet-rich plasma. The inhibitory potency of prostaglandin El increased slightly with prolonged incubation in platelet-rich plasma at 37°C. In rat platelet-rich plasma, dithiothreitol progressively inhibited aggregation in the concentration range 0.5-3.0m~. With higher concentrations, a small direct aggregation response was obtained. In human platelet-rich plasma, dithiothreitol produced significant inhibition of ADP aggregation at 0.1-0.5m. Concentrations of 5 n i~ and above invariably produced large aggregation responses, but at intermediate concentrations there was considerable variability between subjects; in some cases dithiothreitol caused aggregation directly at l . O m~, but in most subjects dithiothreitol was inhibitory up to 3 m~ (Fig. 1) .
N-Ethylmaleimide progressively inhibited platelet aggregation in the concentration range 0.05-0.5m~ in both rat and human platelet-rich plasma. I . G O values were Concn. of dithiothreitol (mM) Fig. 1 . Dose-response curve for dithiothreitol-induced aggregation of human and rat platelets Samples (0.1 ml) of human ( 0 ) or rat (0) citrated platelet-rich plasma were preincubated for 2min at 37°C before the addition of dithiothreitol. Aggregation responses were recorded for 5min and results were expressed as the maximum rate of change of light transmission, 0. I5-0.2m in both species. If concentrations of Nethylmaleimide greater than 0 . 5 m~ were used, the inhibitory effect decreased slightly, because at these concentrations N-ethylmaleimide itself releases constituents from the platelets, and this helps to promote aggregation.
When the inhibitory effect of prostaglandin El in human platelet-rich plasma was tested in the presence of increasing concentrations of dithiothreitol, the inhibition by prostaglandin El was augmented by low concentrations of dithiothreitol(0.1-0.5m~) and decreased by higher concentrations of dithiothreitol(3-10m~). The point at which this change in response occurred varied in different subjects, but it always corresponded to the concentration at which dithiothreitol itself caused platelet aggregation. When the responses to prostaglandin El and dithiothreitol, alone and in combination were compared, the net effect of both agents together was always a summation of the two individual effects. In rat platelet-rich plasma, dithiothreitol in concentrations up to 3 m~ progressively enhanced the inhibitory effects of prostaglandin El, and again the net effect was a summation of the individual effects (Fig. 2a) .
N-Ethylmaleimide in concentrations up to 0 . 5 m~ progressively enhanced the inhibitory effect of prostaglandin El in both rat and human platelet-rich plasma. Again the effects of N-ethylmaleimide in combination with prostaglandin El were merely additive (Fig. 26) .
Johnson et al. (1973) showed that the effect of prostaglandin El was altered in the presence of N-ethylmaleimide and dithiothreitol. They concluded that this alteration in response was mediated by changes in the prostaglandin receptor produced by the thiol agents. However, they made no attempt to measure the effects of the thiol agents alone. We have shown that the thiol agents have independent effects on platelet aggregation; similar, although less detailed observations were made previously for both N-ethylmaleimide (Robinson et al., 1963) and dithiothreitol (Born, 1967) . The exact sites at which these inhibitory agents interact with the platelet have not been determined. Prostaglandin El is a potent stimulator of adenylate cyclase, and the subsequent increase in platelet cyclic AMP activity is believed to be responsible for inhibition of aggregation (Marquis el al., 1969) . However, when several inhibitors are compared, there is a poor correlation between the increase in cyclic AMP activity and the degree of inhibition (Haslam & Taylor, 1971) . At concentrations of N-ethylmaleimide which inhibit aggregation, platelet cyclic AMP content is not increased, but the stimulation of platelet adenylate cyclase by prostaglandin El is augmented (Mills & Smith, 1972) . Two points should be emphasized here: first, N-ethylmaleimide may inhibit aggregation directly by a pathway independent of cyclic AMP, and secondly, recent evidence indicates that there are at least two mechanisms involved in the control of platelet adenylate cyclase, only one of which is affected by prostaglandin El (Mills, 1974) .
Dithiothreitol enhances the inhibitory effect of prostaglandin El at concentrations which themselves inhibit aggregation. Antagonism of the prostaglandin El effect is observed only with concentrations of dithiothreitol which cause aggregation directly. This point is clearly demonstrated by the differences between rat and human platelets. The antagonism of the prostaglandin El effect by aggregating concentrations of dithiothreitol can be explained by the observation that dithiothreitol-induced platelet aggregation cannot beinhibited by prostaglandinEl (MacIntyre &Gordon, 1974) . Johnson et al. (1973) reported only antagonism of prostaglandin El by dithiothreitol and apparently observed this at lower concentrations than we did. Since they did not test dithiothreitol alone, we cannot say whether the concentrations of dithiothreitol which they used caused aggregation. We have found wide inter-subject variation in the concentration of dithiothreitol that directly induces platelet aggregation, and it is possible that the subject tested by Johnson et al. (1973) was unusually susceptible to the aggregating effects of dithiothreitol.
In conclusion, we have confirmed that the inhibitory effect of prostaglandin El on platelet aggregation is modified by dithiothreitol and N-ethylmaleimide, but our evidence suggests that these agents act at sites distinct from prostaglandin El and that the net effect of prostaglandin El plus N-ethylmaleimide or dithiothreitol is always merely additive. Samples (0.1 ml) of human or rat citrated platelet-rich plasma were preincubated for 2min at 37°C before the addition of ADP (1-3p~). (a) Dithiothreitol(0) was added to the platelet-rich plasma 9 0 s before ADP. Prostaglandin El (5ng/ml) was added 6 0 s after dithiothreitol(0). (6) N-Ethylmaleimide ( 0 ) was added to the platelet-rich plasma 90s before ADP. Prostaglandin El (5ng/ml) was added 60s after N-ethylmaleimide (0). Inhibition of aggregation was calculated as the percentage decrease in the response compared with controls containing an equivalent volume of iso-osmotic saline. ----, Inhibition due to prostaglandin El alone.
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